Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome October 31, 2019 07:30 ET | Source: NexImmune, Inc. IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplant IND clearance validates Company’s Artificial Immune Modulation [….]
3rd International Cancer Conference and Expo welcomes you as our guest to the City of Baltimore, USA during June 05-07, 2019. i- Cancer USA 2019 aims in “Driving Innovative Cancer Science Towards Precision Medicine”. For more details- https://www.icancerconference.com/ This conference provides a forum for exchange of ideas and authoritative views by eminent personalities in this [….]
Local Entrepreneur Brings Swedish Company AcouSort to BioHealth Capital Region February 26, 2019 For every AstraZeneca, there are hundreds of small biotech startups and scores of life science innovators that are critical to growing the BioHealth Capital Region. For every new biotech flush with investment cash, scores of smart, entrepreneur-scientists with great ideas and technology [….]
Q&A with Jaime Rodriguez-Canales, M.D., FEBP Dr. Rodriguez-Canales is a Senior Pathologist at MedImmune, and Course Director for the recent Multiplex Immunofluorescence in Immune-Oncology Symposium, a Bio-Trac program cosponsored by Medimmune & PerkinElmer (now Akoya Biosciences). After a successful first annual Symposium and Workshop, we had the opportunity to catch up with Course Director, Dr. [….]
